查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985733

神經性貪食症市場：依治療類型、治療環境、通路和最終用戶分類－2026-2032年全球市場預測

Binge Eating Disorder Market by Treatment Type, Treatment Setting, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經性貪食症市場價值將達到 6.2343 億美元，到 2026 年將成長至 6.648 億美元，到 2032 年將達到 9.5157 億美元，複合年成長率為 6.22%。

主要市場統計數據
基準年 2025 6.2343億美元
預計年份：2026年 6.648億美元
預測年份 2032 9.5157億美元
複合年成長率 (%) 6.22%

全面介紹神經性貪食症的臨床、社會和經濟層面，以及採取全面照護方法的必要性。

神經性貪食症（BED）是一種具有臨床意義的飲食障礙，其特徵是反覆出現大量進食和喪失自控能力的情況。除了診斷標準之外，這種疾病還會產生多方面的臨床、心理和社會影響，影響所有年齡層和所有醫療機構的患者。 BED 患者通常伴隨情緒障礙、焦慮障礙、代謝併發症和功能障礙，因此需要採用協作式的多學科治療方法來解決這些問題。

神經性貪食症治療生態系統正在發生變革性的變化，涵蓋整個護理過程，包括重塑臨床路徑、引入數位技術以及提高患者參與度。

在技​​術進步、臨床創新和保險公司不斷變化的期望的推動下，神經性貪食症的治療格局正在經歷一場變革。數位療法和遠端醫療平台正在加速患者獲得實證心理治療和自我管理工具，從而實現「階梯式照護」模式，使患者能夠根據需要從基層醫療逐步過渡到專科干預。同時，人們對藥物治療和輔助性治療的興趣日益濃厚，促使人們重新評估整體治療策略，這些策略旨在支持患者參與心理治療，並利用藥物治療來減輕症狀嚴重程度。

評估 2025 年美國關稅變化對治療供應鏈和跨境臨床合作的累積影響。

影響關稅的政策措施可能會對整個醫療保健生態系統產生累積效應，尤其會影響到支持藥品、醫療設備以及用於治療神經性貪食症的數位平台的供應鏈。提高進口藥品和醫療設備的關稅可能導致醫療服務提供者和保險公司的成本上升，促使供應鏈管理者調整籌資策略、增加庫存或加速將製造地遷至更靠近終端市場的位置。這些供應方的因應措施反過來又會影響醫院、專科醫療中心和分銷合作夥伴之間的採購週期和合約談判。

透過細分洞察治療類型、分銷管道、最終用戶人口統計特徵和治療環境如何影響臨床路徑和醫療保健服務。

了解神經性貪食症的治療模式需要對治療方法、分銷管道、最終用戶和治療環境等方面的細分市場進行詳細分析。根據治療類型，市場可分為數位療法、藥物療法和心理療法，並進行相應研究。數位療法又可細分為行動應用和網頁版兩種模式；藥物療法可細分為抗憂鬱症、抗驚厥藥和興奮劑；心理療法可細分為認知行為療法、辯證行為療法和人際關係療法。每個細分市場都有其獨特的監管、臨床療效檢驗和商業化要求。數位療法需要證明其在數位終端上的使用者參與度和臨床療效；藥物療法需要經過安全性和標籤核准流程；而心理療法則需要對從業人員進行培訓並監測治療依從性，才能有效擴大規模。

區域性見解比較盛行率、醫療保健基礎設施、報銷和創新採納——這些因素會影響獲得治療和服務的機會。

區域趨勢對神經性貪食症的辨識、治療和報銷有顯著影響，進而塑造臨床計畫和產業計畫的策略重點。在美洲，醫療專業人員意識的提高和遠端醫療正在推動整合式醫療模式的廣泛應用，但公共和私人保險公司政策的區域差異意味著報銷和就醫途徑在不同地區存在顯著差異。因此，需要與保險公司和醫療系統進行本地合作，透過結果和成本抵銷分析來證明其價值。

從企業層面深入了解治療和數位治療提供者的策略定位、合作夥伴關係、研究重點和差異化。

神經性貪食症領域的企業策略由臨床創新、策略夥伴關係和目標明確的商業化模式共同構成。領先的臨床開發公司和數位療法提供者正致力於進行嚴格的療效評估，並透過隨機對照試驗和真實世界數據來驗證療效，從而推動與支付方的對話。同時，技術提供者與成熟的行為健康網路之間的合作，正在推動試點計畫將數位工具整合到現有的診療路徑中，從而降低臨床醫生採用和患者入院的障礙。

為領導者提供切實可行的建議，以加快實施速度，加強護理路徑，並調整策略以適應不斷變化的臨床和監管環境。

業界領導者應推動一系列切實可行的舉措，在保障商業性可行性的同時，加速實證醫療服務的普及。首先，應優先發展整合式醫療模式，將心理治療介入與藥物治療和數位療法結合，並投資於長期療效評估，以證明其臨床和經濟價值。其次，應開發互通性和便於臨床醫師使用的工作流程，使數位療法無縫融入日常診療，進而降低應用門檻，提高病患依從性。

高度透明的調查方法，明確規定了資料來源、分析框架、檢驗程序和品管，以確保嚴謹且可重複的見解。

本報告採用主導調查方法，基於多資訊來源，旨在最大限度地提高可靠性和透明度。主要資料來源包括同儕審查的臨床文獻、註冊登記和臨床試驗資料庫、監管文件，以及對臨床醫生、保險公司、數位醫療創新者和供應鏈專家的定性訪談。這些資訊來源經過交叉檢驗，以校正研究設計、患者族群和結果指標的差異，並評估臨床效果在不同背景下的穩健性。

一份權威的綜合分析報告，重點闡述了戰略重點、綜合護理的緊迫性，並為臨床和政策領域的相關人員指明了未來行動的明確方向。

神經性貪食症的現狀既充滿機會也面臨挑戰。數位療法的進步、藥物研究的重新運作以及不斷演進的照護模式正在為改善治療的可及性和療效開闢道路，但要充分發揮這些潛力，需要臨床、商業和政策相關人員的通力合作。整合心理治療、藥物治療和數位支援的綜合護理路徑對於實現持久療效和減少復發至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的暴食症飲食失調市場

  • 數位療法
    • 行動應用
    • 基於網路的
  • 藥物治療
    • 抗憂鬱症
    • 抗癲癇藥物
    • 興奮劑
  • 心理治療
    • 認知行為療法
    • 辯證行為療法
    • 人際關係療法

第9章：依治療環境分類的貪食症飲食失調市場

  • 住院治療
  • 門診

第10章：暴食症飲食失調市場：依通路分類

  • 家庭醫療保健
  • 醫院和診所
  • 線上平台
  • 專業治療中心

第11章：暴食症飲食失調市場：依最終用戶分類

  • 青年
  • 成人
  • 老年人

第12章：暴食症飲食失調市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：暴食症飲食失調市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：暴食症飲食失調市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國暴食症市場

第16章：中國暴食症市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alsana, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc. by SK Capital Partners LLP
  • BALANCE Eating Disorder Treatment Center
  • Carolina House Eating Disorder Treatment Center
  • Center for Change
  • Equip Health, Inc.
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Innovative Medicine by Johnson and Johnson
  • Monte Nido & Affiliates Holdings, LLC
  • Montecatini Eating Disorder Treatment Center
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Red Oak Recovery
  • Rhodes Pharmaceuticals LP by Purdue Pharma LP
  • SimSon Pharma Limited
  • Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
  • Takeda Pharmaceutical Company Limited
  • TalktoAngel
  • The London Centre for Eating Disorders and Body Image Ltd.
  • TheraCryf Plc
  • Timberline Knolls Residential Treatment Center
  • Viatris Inc.
Product Code: MRR-757B1C9CB0B3

The Binge Eating Disorder Market was valued at USD 623.43 million in 2025 and is projected to grow to USD 664.80 million in 2026, with a CAGR of 6.22%, reaching USD 951.57 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 623.43 million
Estimated Year [2026] USD 664.80 million
Forecast Year [2032] USD 951.57 million
CAGR (%) 6.22%

Comprehensive introduction outlining the clinical, social, and economic dimensions of binge eating disorder and the imperative for integrated care approaches

Binge eating disorder (BED) is a clinically significant eating disorder characterized by recurrent episodes of consuming large amounts of food accompanied by a perceived loss of control. Beyond diagnostic criteria, the condition carries multifaceted clinical, psychological, and social consequences that affect individuals across age groups and care settings. Individuals living with BED often experience comorbid mood and anxiety disorders, metabolic complications, and functional impairment that together require coordinated, multidisciplinary approaches to care.

Recent shifts in care delivery and technology integration have increased awareness among clinicians and payers, yet gaps remain in timely diagnosis, access to evidence-based therapies, and continuity of care after acute intervention. In addition, stigma and underreporting contribute to delayed treatment seeking, particularly among underserved populations. Consequently, clinical leaders and health system administrators are focused on closing care gaps through diagnostic screening in primary care, integration of behavioral health into medical settings, and expanded training on evidence-based psychotherapies.

Given these dynamics, a strategic introduction to the landscape centers on the need for integrated care pathways that combine behavioral interventions, pharmacologic options where clinically appropriate, and digital therapeutics to extend reach. This introduction frames the priorities that follow: optimizing patient identification, aligning care modalities across settings, and ensuring that commercial and policy decisions support durable, equitable access to effective treatment.

Transformative shifts reshaping clinical pathways, digital adoption, and patient engagement in binge eating disorder treatment ecosystems across care continuums

The treatment landscape for binge eating disorder is undergoing transformative shifts driven by technology, clinical innovation, and evolving payer expectations. Digital therapeutics and telehealth platforms have accelerated patient access to evidence-based psychotherapies and self-management tools, enabling stepped-care approaches that begin in primary care and escalate to specialist intervention when needed. Concurrently, renewed interest in pharmacologic agents and adjunctive treatments has prompted a re-examination of combined-modality strategies where medication is used to support engagement in psychotherapy and reduce symptom severity.

Regulatory frameworks and reimbursement models are responding to these changes, with value-based contracting and outcomes-based reimbursement gaining traction in pockets where measurable clinical outcomes can be demonstrated. These dynamics incentivize developers to prioritize real-world evidence generation and validated outcome measures. At the same time, partnerships between digital health innovators, specialty treatment centers, and payers are becoming more common, reflecting a recognition that no single stakeholder can address access, quality, and affordability alone.

As a result, stakeholders must adapt to an ecosystem where patient engagement platforms, clinical decision support tools, and multidisciplinary care teams intersect. Investment in interoperability, clinician training on digital modalities, and robust data governance are necessary to convert technological promise into improved clinical outcomes. Looking forward, integration of behavioral analytics and precision approaches to treatment selection will further reshape care pathways and help personalize interventions for better long-term recovery.

Assessment of cumulative impacts from United States tariff changes in twenty twenty five on therapeutic supply chains and cross-border clinical collaborations

Policy actions affecting tariffs can have a cumulative impact on the broader healthcare ecosystem and specifically on the supply chains that underpin therapeutics, devices, and digital platforms used in binge eating disorder care. Increases in duties on imported pharmaceuticals or medical devices may raise costs for providers and payers, prompting supply chain managers to adjust sourcing strategies, build larger inventories, or accelerate relocation of manufacturing closer to end markets. These supply-side responses, in turn, influence procurement cycles and contract negotiations across hospitals, specialty centers, and distribution partners.

For digital health providers and platform vendors, indirect impacts can also emerge when hardware components, sensors, or ancillary devices are subject to tariff changes. Higher input costs can necessitate price adjustments or altered product roadmaps, while longer lead times for components can slow device-based pilots or rollouts. Clinical trial logistics and international collaboration on research may face friction if cross-border exchanges of equipment or study materials become more costly or administratively burdensome.

Strategic responses to tariff-driven disruption tend to center on diversification and resilience. Organizations are increasingly pursuing nearshoring, dual-sourcing, and advanced inventory management to reduce exposure to single-country policy shocks. They are also engaging earlier with supply chain and procurement teams when designing clinical programs to account for potential cost and timing variability. Moreover, meaningful contingency planning and transparent communication with payers and provider partners enable smoother transitions and protect patient continuity of care during periods of regulatory and trade uncertainty.

Segmentation insights on how treatment type, distribution channel, end-user demographics, and treatment setting influence clinical pathways and care delivery

Understanding how care is delivered for binge eating disorder requires a granular look at segmentation across treatment modality, distribution, end users, and care setting. Based on Treatment Type, the market is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further studied across Mobile App and Web Based delivery models, Pharmacotherapy further studied across Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further studied across Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. These subsegments each present unique regulatory, clinical validation, and commercialization requirements: digital therapeutics must demonstrate engagement and clinical effect across digital endpoints, pharmacotherapies must navigate safety and labeling pathways, and psychotherapeutic modalities require workforce training and fidelity monitoring to scale effectively.

In parallel, distribution channels frame access points for care. Based on Distribution Channel, the market is studied across Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each of which imposes distinct operational needs around clinician workflows, reimbursement codes, and integration with electronic health records. Home healthcare and online platforms expand reach into patient daily environments but require robust remote monitoring and privacy safeguards. Hospitals and clinics provide diagnostic capacity and acute management, while specialty treatment centers concentrate expertise for complex or refractory cases.

Patient populations shape demand and design of services. Based on End User, the market is studied across Adolescents, Adults, and Elderly populations, and differentiation by age group influences clinical features, comorbidity profiles, and engagement preferences. Adolescents may access school-based screening and family-centered interventions, adults often require integrated management for metabolic comorbidities, and elderly patients need attention to polypharmacy and age-specific psychosocial supports. Finally, the setting in which care is delivered matters. Based on Treatment Setting, the market is studied across Inpatient and Outpatient environments, with inpatient care reserved for high-acuity stabilization while outpatient services form the backbone of long-term recovery and relapse prevention. Recognizing these segmentation layers enables stakeholders to align product design, reimbursement strategies, and clinical pathways to meet the needs of distinct user cohorts and care settings.

Regional insights comparing prevalence, care infrastructure, reimbursement, and innovation adoption that shape treatment access and service delivery

Regional dynamics exert strong influence on how binge eating disorder is identified, treated, and reimbursed, and they therefore shape strategic priorities for clinical programs and commercial planning. In the Americas, higher clinician awareness and expanding telehealth infrastructure support broader rollout of integrated care models, but regional heterogeneity in public and private payer policies means that reimbursement and access pathways vary significantly between jurisdictions. This drives a need for localized engagement with payers and health systems to demonstrate value through outcomes and cost-offset analyses.

In Europe, Middle East & Africa, regulatory frameworks and cultural context differ across countries, which affects adoption patterns. Some European markets have established behavioral health integration and national guidelines that facilitate standardized care pathways, while other jurisdictions within the Middle East and Africa are at earlier stages of diagnostic capacity and workforce development. These differences necessitate tailored approaches that consider local clinical training, stigma reduction, and infrastructure investments to expand access.

The Asia-Pacific region presents diverse opportunities and challenges due to variation in digital adoption, population demographics, and regulatory regimes. High mobile penetration in many Asia-Pacific markets supports rapid diffusion of mobile app-based interventions, yet language, cultural norms around eating behavior, and evolving reimbursement policies require careful localization of clinical content and engagement models. Across all regions, stakeholders benefit from region-specific evidence, partnerships with local clinical leaders, and capacity-building initiatives that reflect each region's unique epidemiology and healthcare delivery architecture.

Company-level insights on strategic positioning, collaborations, research priorities, and differentiation among treatment and digital therapy providers

Company strategies in the binge eating disorder landscape are defined by a mix of clinical innovation, strategic partnerships, and targeted commercialization models. Leading clinical developers and digital therapy providers are investing in rigorous outcome measurement, demonstrating efficacy through randomized studies and real-world evidence to support payer conversations. At the same time, alliances between technology providers and established behavioral health networks are enabling pilots that integrate digital tools into existing care pathways, reducing friction for clinician adoption and patient onboarding.

Pharmaceutical stakeholders pursuing pharmacologic options are focusing on differentiation through mechanism of action, tolerability, and evidence of sustained symptom reduction, while also considering the role of adjunctive use with psychotherapy. Specialty treatment centers and hospital systems are exploring value-based contracting arrangements tied to measurable recovery metrics, which encourages providers to report outcomes and iterate on care delivery models. New entrants are leveraging data science to refine patient segmentation and identify which interventions are most likely to succeed for particular patient profiles, creating opportunities for personalized care solutions.

Across the sector, the most successful organizations combine clinical credibility with distribution acumen, prioritizing interoperability, clinician engagement, and payer alignment. They also maintain flexible commercialization roadmaps that allow rapid local adaptation, accelerated partnership models, and investment in training programs to ensure fidelity to evidence-based interventions.

Actionable recommendations for leaders to accelerate adoption, strengthen care pathways, and align strategies with changing clinical and regulatory landscapes

Industry leaders should pursue a set of actionable initiatives that accelerate access to evidence-based care while protecting commercial viability. First, prioritize integrated care models that combine psychotherapeutic interventions with pharmacologic and digital options, and invest in longitudinal outcome measurement to demonstrate clinical and economic value. Second, develop interoperability and clinician-friendly workflows that make digital therapeutics a seamless component of routine care, thereby lowering adoption barriers and improving adherence.

Third, strengthen payer engagement by co-designing outcome frameworks and piloting value-based reimbursement models that reward sustained recovery rather than episodic service delivery. Fourth, insulate supply chains against policy shocks and trade disruptions through diversification, nearshoring where feasible, and transparent procurement strategies that account for potential tariff impacts. Fifth, invest in workforce capacity through clinician training programs focused on evidence-based psychotherapies and on integrating digital tools into therapeutic practice.

Finally, adopt an evidence-first commercialization strategy that sequences clinical validation, payer pilots, and provider partnerships to build credibility and scale. By aligning product development with clear clinical endpoints and payer needs, organizations can reduce commercial risk and accelerate uptake while maintaining ethical standards and patient-centered design principles.

Transparent methodology outlining data sources, analytical frameworks, validation steps, and quality controls to ensure rigorous and reproducible insights

The analysis underpinning this report uses a multi-source, evidence-driven methodology designed to maximize reliability and transparency. Primary inputs include peer-reviewed clinical literature, registry and trial databases, regulatory documents, and qualitative interviews with clinicians, payers, digital health innovators, and supply chain experts. These inputs were triangulated to reconcile differences in study design, patient populations, and outcome measures, and to assess the robustness of clinical effects across settings.

Quantitative findings were supplemented with qualitative insights from subject-matter experts and frontline providers to contextualize adoption barriers and implementation considerations. Data curation and synthesis followed a reproducible protocol: source provenance was recorded, analytical assumptions were documented, and internal replication checks were performed. Validation steps included cross-checking clinical effect estimates against trial registries, reviewing reimbursement pathways with payer consultants, and testing supply chain scenarios with procurement specialists to ensure scenario plausibility.

Limitations are acknowledged: evidence quality varies by intervention type, and some emerging modalities have limited long-term outcome data. To mitigate these constraints, the methodology emphasizes transparency and recommends ongoing evidence generation post-deployment. This approach supports decision-makers who require both rigor and practical guidance when planning clinical programs, commercial launches, or policy engagement.

Conclusive synthesis emphasizing strategic priorities, urgency of integrated care, and a clear pathway forward for stakeholders across clinical and policy domains

The landscape for binge eating disorder is characterized by both opportunity and complexity. Advances in digital therapeutics, renewed pharmacologic inquiry, and evolving care models collectively create avenues to improve access and outcomes, but realizing that potential requires coordinated action across clinical, commercial, and policy stakeholders. Integrated care pathways that bring together psychotherapy, pharmacotherapy, and digital supports are central to delivering sustained benefit and reducing relapse.

At the same time, external forces such as trade policy changes and regional differences in reimbursement and infrastructure introduce practical constraints that demand resilient supply chains, localized engagement strategies, and an evidence-driven approach to payer conversations. Organizations that invest in interoperability, real-world evidence generation, and clinician training will be better positioned to convert scientific advances into meaningful, scalable care.

In summary, the most effective path forward combines clinical rigor with operational resilience and stakeholder collaboration. By aligning investments with clear outcome metrics and by designing services that reflect the lived experience of patients across diverse settings and regions, stakeholders can advance both clinical and commercial goals while expanding equitable access to effective treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Binge Eating Disorder Market, by Treatment Type

  • 8.1. Digital Therapeutics
    • 8.1.1. Mobile App
    • 8.1.2. Web Based
  • 8.2. Pharmacotherapy
    • 8.2.1. Antidepressants
    • 8.2.2. Antiepileptics
    • 8.2.3. Stimulants
  • 8.3. Psychotherapy
    • 8.3.1. Cognitive Behavioral Therapy
    • 8.3.2. Dialectical Behavior Therapy
    • 8.3.3. Interpersonal Psychotherapy

9. Binge Eating Disorder Market, by Treatment Setting

  • 9.1. Inpatient
  • 9.2. Outpatient

10. Binge Eating Disorder Market, by Distribution Channel

  • 10.1. Home Healthcare
  • 10.2. Hospitals And Clinics
  • 10.3. Online Platforms
  • 10.4. Specialty Treatment Centers

11. Binge Eating Disorder Market, by End User

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Elderly

12. Binge Eating Disorder Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Binge Eating Disorder Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Binge Eating Disorder Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Binge Eating Disorder Market

16. China Binge Eating Disorder Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alsana, Inc.
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc. by SK Capital Partners LLP
  • 17.8. BALANCE Eating Disorder Treatment Center
  • 17.9. Carolina House Eating Disorder Treatment Center
  • 17.10. Center for Change
  • 17.11. Equip Health, Inc.
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Jazz Pharmaceuticals plc
  • 17.14. Johnson & Johnson Innovative Medicine by Johnson and Johnson
  • 17.15. Monte Nido & Affiliates Holdings, LLC
  • 17.16. Montecatini Eating Disorder Treatment Center
  • 17.17. Novo Nordisk A/S
  • 17.18. Pfizer Inc.
  • 17.19. Red Oak Recovery
  • 17.20. Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P.
  • 17.21. SimSon Pharma Limited
  • 17.22. Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. TalktoAngel
  • 17.25. The London Centre for Eating Disorders and Body Image Ltd.
  • 17.26. TheraCryf Plc
  • 17.27. Timberline Knolls Residential Treatment Center
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BINGE EATING DISORDER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BINGE EATING DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY MOBILE APP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ANTIEPILEPTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY STIMULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DIALECTICAL BEHAVIOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INTERPERSONAL PSYCHOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BINGE EATING DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BINGE EATING DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BINGE EATING DISORDER MARKET SIZE, BY DIGITAL THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BINGE EATING DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BINGE EATING DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BINGE EATING DISORDER MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BINGE EATING DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BINGE EATING DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)